Portal de Periódicos da CAPES

Bladder tumour development after urothelial carcinoma of the upper urinary tract is related to primary tumour location

2006; Wiley; Volume: 98; Issue: 6 Linguagem: Inglês

10.1111/j.1464-410x.2006.06519.x

1464-410X

Richard Zigeuner, Georg C. Hutterer, Thomas Chromecki, Peter Rehak, Cord Langner,

Renal cell carcinoma treatment

OBJECTIVE To better define the predictors of bladder tumour development in patients operated for upper urinary tract urothelial cancer (UT‐UC). PATIENTS AND METHODS Surgical specimens from 191 consecutive patients with no history of bladder cancer and operated for UT‐UC were chosen for analysis. Bladder tumour development was assessed in relation to UT‐UC location, tumour multiplicity, stage and grade, margin status, mode of operation, age and gender. RESULTS Overall, 51 of 191 (27%) patients developed subsequent bladder tumours, including 25 of 123 (20%) with pelvic, 19 of 47 (40%) with ureteric and seven of 21 (33%) with multifocal tumours ( P = 0.04 for all subgroups; P = 0.01 for pelvic vs ureteric). There was no influence of the other variables. The median (mean, range) time to recurrence was 12 (18, 3–64) months. In a multivariate analysis, ureteric tumour location was an independent predictor ( P = 0.02; risk ratio, RR, 2.0, 95% confidence interval, CI, 1.1–3.7). After excluding 68 patients with systemic disease progression, bladder tumour development was noted in 39 of 123 (32%), including 18 of 76 (24%) with pelvic, 16 of 34 (47%) with ureteric and five of 13 with multifocal tumours ( P = 0.06 for all subgroups; P = 0.02 for pelvic vs ureteric). In a multivariate analysis, ureteric location ( P = 0.03; RR 2.1, 95% CI 1.1–4.2) and high tumour grade ( P = 0.04; RR 2.2, 95% CI 1.03–4.7) were independent predictors of subsequent bladder tumour development. CONCLUSION The risk of developing a bladder tumour after surgery for UT‐UC is significantly related to ureteric tumour location and high tumour grade. Clinical trials to evaluate a possible reduction of bladder cancer risk by intraoperative ureteric ligation and/or peri‐operative topical intravesical chemotherapy instillation are justified.